Zynerba Pharmaceuticals Inc.

ZYNE on NASDAQToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
3.47US -0.14/-3.88%386,6972.55 / 16.4781.74 M

Contact Information

Zynerba Pharmaceuticals Inc.

Headquarters:
80 W. Lancaster Avenue, 300
Devon, Pennsylvania
USA, 19333
Tel: 484-581-7505
Website: Visit website
For more information...
Lead: John Boidman

Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Learn more at www.zynerba.com and follow us on Twitter at @ZynerbaPharma.  

Armando Anido - Chairman of the Board and Chief Executive Officer

Terri B. Sebree - President

Jim Fickenscher - Chief Financial Officer, Vice President, Corporate Development

Joe Apostolico - Vice President, Human Resources

Donna L. Gutterman, PharmD - Vice President, Medical

Suzanne M. Hanlon - Vice President and General Counsel

Terry Hurst - General Manager, Zynerba Pharmaceuticals Pty Ltd (Australia)

Ray Mannion - Vice President, Manufacturing

Carol O’Neill - Vice President, Development

Joseph M. Palumbo, MD, FAPA, MACPsych - Chief Medical Officer

Will Roberts - Vice President, Investor Relations and Corporate Communications

Brian Rosenberger - Vice President, Commercial and Business Development

Nancy Tich, PhD - Vice President, Clinical

Armando Anido - Chairman of the Board and Chief Executive Officer

Warren D. Cooper, MB, BS, BSc, MFPM - Lead Independent Director

John P. Butler

William J. Federici

Daniel L. Kisner, M.D.

Kenneth I. Moch

Pamela Stephenson

Stock Information

Company Overview

Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Learn more at www.zynerba.com and follow us on Twitter at @ZynerbaPharma.  

Management

Armando Anido - Chairman of the Board and Chief Executive Officer

Terri B. Sebree - President

Jim Fickenscher - Chief Financial Officer, Vice President, Corporate Development

Joe Apostolico - Vice President, Human Resources

Donna L. Gutterman, PharmD - Vice President, Medical

Suzanne M. Hanlon - Vice President and General Counsel

Terry Hurst - General Manager, Zynerba Pharmaceuticals Pty Ltd (Australia)

Ray Mannion - Vice President, Manufacturing

Carol O’Neill - Vice President, Development

Joseph M. Palumbo, MD, FAPA, MACPsych - Chief Medical Officer

Will Roberts - Vice President, Investor Relations and Corporate Communications

Brian Rosenberger - Vice President, Commercial and Business Development

Nancy Tich, PhD - Vice President, Clinical

Board of Directors

Armando Anido - Chairman of the Board and Chief Executive Officer

Warren D. Cooper, MB, BS, BSc, MFPM - Lead Independent Director

John P. Butler

William J. Federici

Daniel L. Kisner, M.D.

Kenneth I. Moch

Pamela Stephenson

Contact Information

Headquarters:
80 W. Lancaster Avenue, 300
Devon, Pennsylvania
19333, USA
Telephone: 484-581-7505
Website: Visit website